Pharmacogenomic studies have been underway for several years in neuropsychiatry, yet the field still seems in its infancy. Many early studies suffered from a lack of large study cohorts and high-throughput molecular technology, which only became available relatively recently. More recent studies have generated promising leads, but effect sizes remain small and replication studies in large samples are generally lacking.
